Abstract:Abstract There is increasing evidence that B cells play a significant role in the immunobiology of melanoma; however, reports of the pro- vs. antitumour roles of B cells are inconsistent. We hypothesized that advanced melanoma favours regulatory B-cell phenotypes and class switching to less effective antibody isotypes. We conducted an in-depth characterization of the circulating humoral compartment in patients with advanced stage III/IV melanoma (n = 46), compared to healthy volunteers (n = 16). Phenotyping of circulating B cells was performed using B-cell-directed mass cytometry (CyTOF); serum immunoglobulin antibody isotyping was conducted using multiplex immunoassay; and immuno-mass spectrometry was employed to screen serum IgGs for autoantibodies against > 13 000 candidate human proteins. The melanoma B-cell compartment was enriched in naïve CD21lo B cells, plasmablasts and double-negative B cells, compared to samples from healthy controls. These populations shared significant characteristics with phenotypes enriched in classical autoimmune diseases, most notably systemic lupus erythematosus (SLE). An enriched plasmablast population showed the highest median scaled expression of regulatory B-cell markers interleukin (IL)-10 and CD95 (Fas) of all B-cell populations, suggesting a potential immunosuppressive role. Consistent with an IL-10-enriched, T helper 2-biased environment, serum antibody isotyping revealed enrichment of IgG4, a less effective antibody isotype that may promote tumour propagation, in patients with melanoma, compared to healthy controls. In support of an autoreactive immune response, immuno-mass spectrometry screening of serum IgGs revealed altered autoreactivity in sera from patients with melanoma vs. with healthy control sera. Some autoantibodies were found exclusively in patients with melanoma, and these were reactive against human proteins recognized in carcinogenesis and proteins localized to the skin. Correlations between autoreactivity to tubulin cytoskeletal components and tumour burden was also identified. These findings show parallels with SLE, where one of the principal defects is an increased presence of apoptotic cell components and a breakdown of tolerance to cell-associated autoantigens. This may also suggest that localized immune reactivity in the tumour microenvironment may be reflected in an altered regulatory and autoreactive circulating humoral compartment. Our data identify distinct immature and regulatory B-cell signatures in patients with advanced melanoma that share characteristics with those reported in autoimmune diseases. Tumour-associated immune suppression may skew class switching to less effective antibody isotypes and toward regulatory B-cell phenotypes likely to favour tumour progression.

B cells and antibody production in melanoma

O20 Advanced Melanoma is Associated with Distinct Circulating B-cell Profiles Enriched with Immunoregulatory and Autoreactive Features

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Applications of Melanin and Melanin-Like Nanoparticles in Cancer Therapy: A Review of Recent Advances

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Neglected no more: B cell-mediated anti-tumor immunity

B cells and tertiary lymphoid structures promote immunotherapy response

The Emerging Role of B Cells in Tumor Immunity.

Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?

Participation of B cell in immunotherapy of cancer

B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients

Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment

B-cell-specific checkpoint molecules that regulate anti-tumour immunity

Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma

Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers

Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy

The Immune-Related Role of Beta-2-microglobulin in Melanoma

B cell regulation of the anti-tumor response and role in carcinogenesis

Bispecific Antibodies Progression in Malignant Melanoma